Document Detail

Primitive neuroectodermal tumor of the cervix: a case report.
Jump to Full Text
MedLine Citation:
PMID:  21962148     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Peripheral primitive neuroectodermal tumor of the cervix uteri is extremely rare. Between 1987 and 2010, there were only nine cases reported in the English literature, with considerably different management policies.
CASE PRESENTATION: A 45-year-old Iranian woman presented to our facility with a primitive neuroectodermal tumor of the cervix uteri. Her clinical stage IB2 tumor was treated successfully with chemotherapy. Our patient underwent radical hysterectomy. There was no trace of the tumor after four years of follow-up.
CONCLUSIONS: According to current knowledge, primitive neuroectodermal tumors belong to the Ewing's sarcoma family, and the improvement of treatment outcome in our patient was due to dose-intensive neoadjuvant chemotherapy, surgery and consolidation chemotherapy in accordance with the protocol for bony Ewing's sarcoma.
Authors:
Farah Farzaneh; Hamidreza Rezvani; Parisa Taherzadeh Boroujeni; Farzaneh Rahimi
Related Documents :
286828 - Carcinogenicity of n-nitrosobis(2-hydroxypropyl)amine and n-nitrosobis(2-oxopropyl)amin...
197438 - The induction of tumors in rana temporaria with nitrosamines.
21602658 - Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patien...
3567308 - On the efficiency of age-adjusted tests in animal carcinogenicity experiments.
2591428 - Role of natural killer cells in bladder tumor.
18614858 - Cancer gene therapy of adenovirus-mediated anti-4-1bb scfv in immunocompetent mice.
Publication Detail:
Type:  Journal Article     Date:  2011-09-30
Journal Detail:
Title:  Journal of medical case reports     Volume:  5     ISSN:  1752-1947     ISO Abbreviation:  J Med Case Rep     Publication Date:  2011  
Date Detail:
Created Date:  2011-10-20     Completed Date:  2011-11-10     Revised Date:  2012-11-09    
Medline Journal Info:
Nlm Unique ID:  101293382     Medline TA:  J Med Case Rep     Country:  England    
Other Details:
Languages:  eng     Pagination:  489     Citation Subset:  -    
Affiliation:
Department of Medical Oncology, Taleghani Hospital, Tehran, Iran. medicalresco@yahoo.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): J Med Case Reports
ISSN: 1752-1947
Publisher: BioMed Central
Article Information
Download PDF
Copyright ©2011 Farzaneh et al; licensee BioMed Central Ltd.
open-access:
Received Day: 19 Month: 9 Year: 2009
Accepted Day: 30 Month: 9 Year: 2011
collection publication date: Year: 2011
Electronic publication date: Day: 30 Month: 9 Year: 2011
Volume: 5First Page: 489 Last Page: 489
ID: 3197535
Publisher Id: 1752-1947-5-489
PubMed Id: 21962148
DOI: 10.1186/1752-1947-5-489

Primitive neuroectodermal tumor of the cervix: a case report
Farah Farzaneh1 Email: farahzaneh@yahoo.com
Hamidreza Rezvani2 Email: medicalresco@yahoo.com
Parisa Taherzadeh Boroujeni3 Email: thrzdh@yahoo.com
Farzaneh Rahimi4 Email: Farzirahimi@yahoo.com
1Infertility and Reproductive Health Research Center, Department of Obstetrics & Gynecology, Taleghani Hospital, Tehran, Iran
2Department of Medical Oncology, Taleghani Hospital, Tehran, Iran
3Department of Obstetrics & Gynecology, Taleghani Hospital, Tehran, Iran
4Department of Cytopathology, Taleghani Hospital, Tehran, Iran

Introduction

Peripheral primitive neuroectodermal tumor (PNET) of the cervix is extremely rare, and to the best of our knowledge between 1987 and 2010 only nine cases were described in the English literature [1-8]. The protocol for treatment in these previous cases varied considerably, partly due to the rarity of the disease and partly due to the different time periods of diagnosis and treatment.


Case presentation

A 45-year-old Iranian woman presented to our University Hospital with a PNET of the cervix. After clinical staging and discussion at our Gynecology Oncology Multidisciplinary Team (GOMDT) meeting, treatment began.

Our patient was multiparous and had initially presented to a local regional facility with yellow purulent vaginal discharge for the last three months. Upon examination by a gynecologist, a biopsy was taken from a bulging cervical tumor, and a diagnosis of a small round cell malignant tumor was made based on analysis of the sample. Our patient was then referred to our center. Bimanual pelvic examination under general anesthesia revealed a 4 × 5 cm mass apparently arising from the anterior lip of the cervix, producing yellow vaginal discharge; the size of the uterus was around the size of a 10 week pregnancy. There was no extension of the lesion into the vagina, parametria, or adjacent organs including the bladder and rectum. The tumor was clinically at stage IB2. A repeat cervical biopsy was taken for confirmation of the tumor type, which was prepared and analyzed by an expert cytopathologist using immunohistochemistry (IHC).

The slides of the biopsy taken in the regional hospital were revised, and additional tumor material from the second biopsy taken in our institute was examined. Both biopsies showed the same histological appearances: small blue-staining tumor cells with little cytoplasm lying closely packed in sheets without rosette or gland formation. The cytoplasm of the tumor cells was clearly shown to contain glycogen on staining with periodic acid-Schiff (PAS). Immunohistochemistry stains for a number of epithelial markers were negative including CD3, terminal deoxynucleotidyl transferase (TdT), desmin, latent class analysis (LCA), neurofilament, CD10, CD20, cytokeratin, and carcinoembryonic antigen (CEA). However CD99, chromogranin, and synaptophysin showed strong positivity and neuron-specific enolase (NSE) was focally positive. On the basis of these findings, a diagnosis of PNET of the cervix was made.

Laboratory examination results from hematology, electrolyte, liver and renal function tests were normal. Spiral computerized tomography (CT) scanning of the chest and abdomen showed multiple para-aortic adenopathies (20 mm in diameter). The results of rectosigmoidoscopy, as well as a whole body scan, were normal. There were no signs of lung or liver metastasis.

After discussion in our GOMDT meeting, it was decided to treat our patient in the following manner: (1) Initially, our patient would received a neoadjuvant chemotherapy regimen consisting of vincristine 2 g, adriamycin 75 mg/m2, cyclophosphamide 1200 mg/m2 (VAC) alternating with ifosfamide 1800 mg/m2 plus etoposide 100 mg/m2 during days 1 to 5; (2) then, surgical treatment would be performed consisting of hysterectomy and bilateral oophorectomy with or without lymphadenectomy depending on the findings at surgery; (3) finally, chemotherapy or radiotherapy depending on the findings at surgery and microscopic examination would be started. A decision regarding consolidation therapy would then ensue.

At the end of 12 weeks of chemotherapy, there was a complete response of the primary tumor, and enlarged para-aortic lymph nodes were revealed on CT scan. A radical hysterectomy was therefore performed involving the uterus and bilateral ovaries along with the proximal third of the vagina, and the bilateral parametrium, which were all removed. At the time of surgery there were no enlarged pelvic or para-aortic lymph nodes. As the para-aortic lymph nodes were not biopsied before chemotherapy due to our patient's condition, we decided to perform a complete para-aortic and pelvic lymphadenectomy in addition to a radical hysterectomy. Unfortunately, our patient's general condition prohibited a complete para-aortic and pelvic lymphadenectomy, so only sampling of the pelvic nodes was performed.

A macroscopic examination showed a tumor of 5 × 6 × 5 cm in the cervical location (Figure 1). Microscopic examination of the removed tumor tissue showed a small round cell tumor of the cervix with a depth of 8 mm to the stroma. In the histological examination of uterus, vagina and parametrium no malignancy was reported. No lymphovascular invasion was reported. Only three pelvic nodes from the pelvic left side and right pelvic nodes were found along with the specimen, which was negative for malignancy. All the pathology reports were reviewed by another expert pathologist (Figures 2, 3, 4, 5).

After surgery, the same chemotherapy protocol was continued for another 12 weeks. Finally, after completion of the treatment, chest and abdomen CT scans consistently showed no enlargement of lymph nodes and no sign of tumor.

Over more than four years of follow-up in our out-patient clinic (every month for three months, then every three months for the first year, then every six months to date by the gynecologic oncologist and medical oncologist) there was no recurrence of the disease seen on either physical examination or CT imaging.


Discussion

Our patient was diagnosed as having at least clinical stage IB2 cervical cancer at the time of presentation. From the results shown in Table 1, it seems that PNET of the cervix can happen at any age. In a literature review performed by Snijders-Keilholz et al. [9], the range of age at diagnosis of the disease was between 21 and 60 years. PNET of the uterine cervix belongs to the Ewing's sarcoma family [10]. Although such tumors usually occur in younger adults, often around the shoulder or hip, they can arise at many other sites including the uterine cervix. Cytogenetic studies now indicate that Ewing's sarcoma and PNET have similar histological features and should be considered as one entity [10]. In our patient's case, we did not have the facilities to test for the t(11;22) translocation found in Ewing/PNET. However, strong membranous staining with CD99 was very characteristic and sensitive. Chromogranin and synaptophysin test results were also positive. Furthermore, negative staining for a wide variety of other markers including CD3, TdT, desmin, LCA, neurofilament, CD10, CD20, cytokeratin, and CEA excluded other types of small, blue, round cell tumor that entered the differential diagnosis.

Ewing's sarcoma must be considered as a systemic disease without adequate treatment in which more than 90% of patients die from secondary hematogenous metastases, occurring mainly in the lung. Therefore, the five-year survival rate can increase to 55% to 60% with dose-intensive cytotoxic treatment regimens in localized disease; the three-year disease-free survival rate was reported to be 15% to 22% among patients with detectable metastases at time of diagnosis [11].

As shown in Table 1, in earlier reports the approach to treatment of uterine cervix PNET was optimal local surgical treatment followed by additional treatment such as irradiation and/or chemotherapy. Recently however, neoadjuvant chemotherapy followed by local treatment has been favored because of improved results from the addition of systemic therapy. Optimal management must be based on a GOMDT decision. As all 10 cases were at stage IB and mostly with no metastasis at the time of diagnosis, it is assumed that a tumor in this location produces symptoms at an early stage. Although, as can be seen from Table 1, one patient as well as our patient underwent chemotherapy first because the tumor was too large to perform initial radical surgery, the other cases had primary local treatment mainly consisting of primary surgery (except in one patient which was first treated with radiotherapy) followed by additional local radiotherapy or systemic treatment. Metastatic disease developed after three years in one case, and this patient died after a year.

It might be considered that neoadjuvant chemotherapy is an overtreatment for the management of PNET. However, as Snijders-Keilholz et al. [9] mention, up to now duration of follow-up of the reported cases is too short (five to 42 months) to prove or reject this discussion. As with Ewing's sarcoma of other sites, we showed that neoadjuvant chemotherapy in metastatic cases could change an inoperable presentation to an operable state for successful local and/or regional treatment.


Conclusions

Patients with localized PNET of the cervix should be treated with dose-intensive neoadjuvant chemotherapy followed by local treatment, and chemotherapy thereafter. Our patient was treated with a multimodal therapy regime resulting in a disease-free state for at least four years after diagnosis.


Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.


Competing interests

The authors declare that they have no competing interests.


Authors' contributions

FR analyzed and interpreted the data regarding the histological examination of our patient. HR performed the medical treatment, and was a major contributor to writing the manuscript. FF and PT performed the surgical treatment and the follow-up. All authors read and approved the final manuscript.


Acknowledgements

We thank the Taleghani Hospital Staff, especially people working in the Department of Hematology Oncology and Department of Histopathology.


References
Russin VL,Valente PT,Hanjani P,Psammoma bodies in neuroendocrine carcinoma of the uterine cervixActa CytolYear: 1987317917953425140
Sato S,Yajima A,Kimura N,Namiki T,Furuhashi N,Sakuma H,Peripheral neuroepithelioma (peripheral primitive neuroectodermal tumor) of the uterine cervixTohoku J Exp MedYear: 199618018719510.1620/tjem.180.1879111767
Horn LC,Fischer U,Bilek K,Primitive neuroectodermal tumor of the cervix uteri. A case reportGen Diagn PatholYear: 19971422272309065588
Cenacchi G,Pasquinelli G,Montanaro L,Cerasoli S,Vici M,Bisceglia M,Giangaspero F,Martinelli GN,Derenzini M,Primary endocervical extraosseous Ewing's sarcoma/PNETInt J Gynecol PatholYear: 199817838810.1097/00004347-199801000-000159475198
Pauwels P,Ambros P,Hattinger C,Lammens M,Dal Cin P,Ribot J,Struyk A,van den Berghe H,Peripheral primitive neuroectodermal tumour of the cervixVirchows ArchYear: 2000436687310.1007/PL0000820110664164
Tsao AS,Roth LM,Sandler A,Hurteau JA,Cervical primitive neuroectodermal tumorGynecol OncolYear: 20018313814210.1006/gyno.2001.633911585426
Malpica A,Moran CA,Primitive neuroectodermal tumor of the cervix: a clinicopathologic and immunohistochemical study of two casesAnn Diagn PatholYear: 2002628128710.1053/adpa.2002.3573912376920
Goda JS,Nirah B,Mayur K,Pramod P,Udayan K,Primitive neuroectodermal tumour of the cervix: a rare entityInternet J RadiolYear: 20076
Snijders-Keilholz A,Ewing P,Seynaeve C,Burger CW,Primitive neuroectodermal tumor of the cervix uteri: a case report -- changing concepts in therapyGynecol OncolYear: 20059851651910.1016/j.ygyno.2005.05.02015979131
Carvajal R,Meyers P,Ewing's sarcoma and primitive neuroectodermal family of tumorsHematol Oncol Clin North AmYear: 20051950152510.1016/j.hoc.2005.03.00415939194
Antman K,Crowley J,Balcerzak SP,Kempf RA,Weiss RB,Clamon GH,Baker LH,A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcomaCancerYear: 1998821288129510.1002/(SICI)1097-0142(19980401)82:7<1288::AID-CNCR11>3.0.CO;2-29529020

Figures

[Figure ID: F1]
Figure 1 

Macroscopic view of the resected uterus.



[Figure ID: F2]
Figure 2 

Positive MIC2 (CD99) expression in the tumor cells.



[Figure ID: F3]
Figure 3 

Representative hematoxylin and eosin staining of the tumor.



[Figure ID: F4]
Figure 4 

Positive synaptophysin stain in the tumor.



[Figure ID: F5]
Figure 5 

Tumor cells shown to be chromogranin A positive.



Tables
[TableWrap ID: T1] Table 1 

Management of nine patients with primitive neuroectodermal tumor (PNET) of the cervix, as published in the English literature (1987 to 2008)


First author, year, reference Age, gravida/para Clinical stage/metastasis (met) Treatment protocol Follow-up
Russin, 1987 [1] 60 years, 2/2 IB2/no met Internal and external RT. Residual carcinoma in endocervical curettement reason for TAH+BSO+staging laparotomy. Tumor in endocervix and implant in cul-de-sac, reason for six courses of CHT. VAC. Alive 16 months after diagnosis
Sato, 1996 [2] 44 years, 4/2 IB2/no met on whole body X-ray and bone scan negative TAH+LSO+pelvic lymph node dissection (all N neg), followed by unknown no. of courses of cisplatin, etoposide, adriamycin and cyclophosphamide. Second-look operation after 6 months revealed no tumor. Alive 6 months after first operation
Horn, 1997 [3] 26 years, 3/2 IB1/no met after hysterectomy TAH+BSO+pelvic lymphadenectomy (lymphangiosis but no met) followed by RT of the pelvis 3 years later, pulmonary met: CHT (5 FU/cisplatin)+thorax RT. Died 4.2 years after surgery, due to met
Cenacchi, 1998 [4] 36 years IB2/no met on whole body CT after TAH TAH without BSO Alive NED 18 months after surgery
Pauwels, 2000 [5] 45 years IB2/no met TAH (no tumor outside the cervix) followed by pelvic RT Alive 42 months after surgery
Tsao, 2001 [6] 24 years, 3/2 pregnant No bony lesions and no lymph node involvement Pre-operative CHT due to large primary lesion: two alternating cycles of VAC and IE, followed by TAH+transposition of the ovaries and para-aortic LN sampling, followed by two alternating cycles of VAC and IE, and then pelvic RT. No details of survival
Malpica, 2002 [7] 35 years IB1/no met TAH+BSO+selective para-aortic and bilateral pelvic lymphadenectomy followed by adjuvant CHT Alive 5 months after diagnosis
Malpica, 2002 [7] 51 years IB2/no met Same treatment as the previous patient Alive 18 months after diagnosis
Snijders-Keilholz, 2005 [9] 21 years, nulligravid -/no met Six courses of DIME followed by hysterectomy without adnexectomy and without lymphadenectomy followed by 5 courses of VIA Alive 27 months after diagnosis
Goda, 2007 [8] 19 years, nulligravid -/no met Combination CHT with VAC, planned for further consolidation CHT after RT Alive

CHT = chemotherapy; CT = computed tomography; DIME = doxorubicin, Ifosfamide, mesna, etoposide; IE = ifosfamide, etoposide; N neg = lymph node negative; NED = no evidence of disease; RT = radiotherapy; TAH+BSO = total abdominal hysterectomy, bilateral salpingo-oophorectomy; VAC = vincristine, adriamycin, cyclophosphamide; VID = vincristine, ifosfamide, dactinomycin.



Article Categories:
  • Case Report


Previous Document:  Structure-activity studies of diazabicyclo[3.3.0]octane-substituted pyrazines and pyridines as poten...
Next Document:  The predictive value of leukocyte parameters for hypertensive disorders of pregnancy in south China.